Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study
By Abdo A. Elfiky. Life Science, 2020
804 citations recorded by the source corpus.
Aims A new human coronavirus (HCoV), which has been designated SARS-CoV-2, began spreading in December 2019 in Wuhan City, China causing pneumonia called COVID-19. The spread of SARS-CoV-2 has been faster than any other coronaviruses that have succeeded in crossing the animal-human barrier. There is concern that this new virus will spread around the world as did the previous two HCoVs—Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS)—each of which caused approximately 800 deaths in the years 2002 and 2012, respectively. Thus far, 11,268 deaths have been reported from the 258,842 confirmed infections in 168 countries. Main methods In this study, the RNA-dependent RNA polymerase (RdRp) of the newly emerged coronavirus is modeled, validated, and then targeted using different anti-polymerase drugs currently on the market that have been approved for use against various viruses. Key findings The results suggest the effectiveness of Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir as potent drugs against SARS-CoV-2 since they tightly bind to its RdRp. In addition, the results suggest guanosine derivative (IDX-184), Setrobuvir, and YAK as top seeds for antiviral treatments with high potential to fight the SARS-CoV-2 strain specifically. Significance The availability of FDA-approved anti-RdRp drugs can help treat patients and reduce the danger of the mysterious new viral infection COVID-19. The drugs mentioned above can tightly bind to the RdRp of the SARS-CoV-2 strain and thus may be used to treat the disease. No toxicity measurements are required for these drugs since they were previously tested prior to their approval by the FDA.
Subfields: General Health Professions, Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/a7bc3bd1b605a3d015370ea2a624ba3aeabd1106
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
Citations in the corpus
- SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective (2020, methodology): “Four compounds derived from IDX-184 have proved its potency against Zika and Hepatitis C Viruses, and two compounds possess a low binding affinity to RdRp (Cinnamaldehyde and Thymoquinone) are used as negative controls (Elfiky, 2017, 2019; 2020b; Elfiky & Ismail, 2017; 2018; 2019).”
- SARS-CoV-2–triggered neutrophil extracellular traps mediate COVID-19 pathology (2020, methodology): “To investigate this hypothesis, we treated SARS-CoV-2– exposed neutrophils with tenofovir disoproxil fumarate (TDF), an inhibitor of RNA polymerase that has been shown to reduce SARS-CoV-2 replication in Vero cells (Elfiky, 2020; Clososki et al., 2020).”